您的位置: 首页 » 法律资料网 » 法律法规 »

绍兴市城镇集体所有制企业审计监督暂行规定

时间:2024-05-19 18:20:56 来源: 法律资料网 作者:法律资料网 阅读:9186
下载地址: 点击此处下载

绍兴市城镇集体所有制企业审计监督暂行规定

浙江省绍兴市人民政府


绍兴市人民政府文件

绍市府发〔1995〕78号


--------------------------------------------------------------------------------

绍兴市城镇集体所有制企业审计监督暂行规定


 
 
印发《绍兴市城镇集体所有制企业审计监督暂行规定》的通知
绍市府发[1995]78号



各县(市、区)人民政府,市政府各部门:
  现将《绍兴市城镇集体所有制企业审计监督暂行规定》印发给你们,请认真贯彻执行。

  绍兴市人民政府
      一九九五年九月十二日

绍兴市城镇集体所有制企业审计监督暂行规定


  第一条 为了加强对绍兴市城镇(含建制镇)集体所有制企业(以下简称城镇集体企业)的审计监督,维护国家财政经济秩序,保障城镇集体经济的发展,根据《中华人民共和国审计法》和《中华人民共和国城镇集体所有制企业条例》等法律、法规的规定,结合我市实际,制定本规定。
  第二条 绍兴市城镇各种行业、各种组织形式和经营方式的集体企业的财务收支,依照本规定接受审计监督。
  审计机关对前款所列财务收支的真实、合法和效益,依法进行审计监督。其具体审计监督事项是:
  (一)集体资产的保值,增值情况;
  (二)资产、负债和盈亏的真实性,财务收支的真实性、合法性等情况;
  (三)依法纳税情况;
  (四)使用国有金融机构贷款情况和国家税收减免所形成的国家扶持资金的使用管理情况。
  (五)企业法定代表人经营责任情况;
  (六)严重侵占城镇集体资产和损失浪费情况;
  (七)当地政府交办的其他审计事项。
  第三条 审计机关直接审计的企业,由审计机关依照审计管辖权分别确定。
  除审计机关直接审计以外的其他城镇集体企业,逐步实行社会审计查证制度。审计机关根据情况确定必须委托社会审计组织进行审计查证的企业,可委托具有审计查证资格的社会审计组织进行审计,并向审计机关报送审计查证报告和年度会计报表。
  第四条 审计机关对当地财政收入有较大关系,接受财政补贴或享受国家供销、信贷、税收等优惠政策较多,亏损数额较大的城镇集体企业,可以有计划地定期进行审计。
  第五条 审计机关根据本级人民政府或上级审计机关的要求,有权对城镇集体企业有关事项进行专项审计调查,并向本级人民政府和上级审计机关报告审计调查结果。
  第六条 被审计企业应当配合审计机关的工作,并提供有关资料及证明材料和必要的工作条件。对拒绝、拖延提供与审计有关资料,或拒绝、阻碍检查的,审计机关可以责令改正,通报批评,给予警告;拒不改正的,依法追究责任。
  第七条 审计机关对被审计企业违反国家规定的财务收支,以及对集体资产的侵占和损失浪费行为,有权予以制止。
  第八条 审计机关认为被审计企业所执行的上级主管部门有关财务收支的规定与法律、法规和地方性法规、规章相抵触的,应当建议有关主管部门纠正。
  第九条 审计机关根据被审计企业的财政、财务隶属关系,确定审计管辖范围。
  第十条 审计机关及其工作人员办理企业审计事项,应当客观公正、实事求是,对其在执行职务中知悉的国家秘密和被审计单位的商业秘密,负有保守秘密的义务。
  第十一条 审计机关办理企业审计事项,应当依照《中华人民共和国审计法》规定的审计程序及权限开展工作。
  第十二条 审计机关对企业主管部门内部审计机构审计过的事项和委托社会审计机构办理的审计事项保留抽审权,但应当防止不必要的重复审计。
  第十三条 本规定由绍兴市审计局负责解释。
  第十四条 本发自发之日起施行。


浙江省城市供水管理办法(2005年)

浙江省人民政府


浙江省城市供水管理办法

省政府令第207号


《浙江省城市供水管理办法》已经省人民政府第53次常务会议审议通过,现予公布,自公布之日起施行。

省长

二○○五年十二月二日



第一章总则


第一条 为了发展城市供水事业,加强城市供水管理,促进节约用水,保证供水安全,维护供水企业和用户的合法权益,保障生活、生产用水和其他用水,根据《中华人民共和国水法》、《城市供水条例》等有关法律、法规,结合本省实际,制定本办法。

第二条 在本省行政区域内从事城市供水、用水及其相关管理活动均应当遵守本办法。

第三条 省建设行政主管部门主管全省城市供水工作。
市、县(市、区)人民政府城市供水行政主管部门主管本行政区域内的城市供水工作。环境保护、卫生、城市规划、质量技监、国土资源、水利、经贸等有关部门按照各自职责,协助做好城市供水管理工作。

第四条 县级以上人民政府应当加快城市供水事业发展,鼓励从事城市供水科学技术研究,推广先进技术,提高供水质量。

第五条城市供水工作实行开发利用水源与节约用水相结合、保障供水与确保水质相结合的原则。



第二章 城市供水水源管理



第六条 县级以上人民政府应当组织水利、城市规划、城市供水等行政主管部门共同编制城市供水水源开发利用规划,作为城市供水规划的组成部分,纳入城市总体规划。

第七条 城市供水水源开发利用规划应当与水资源开发利用规划、水长期供求计划相协调。

开发、利用水资源,应当优先保证城乡居民生活用水,统筹兼顾工业用水和其他各项建设用水。

第八条 城市供水应当优先开发利用地表水,严格控制开采地下水。

第九条 市、县(市、区)人民政府应当组织环境保护、水利、城市供水、城市规划、卫生等行政主管部门按照国家有关法律、法规和标准,在城市供水水源地划定饮用水水源保护区并报省人民政府批准后公布。

饮用水水源保护区的保护管理,依照水污染防治有关法律、法规的规定执行。

第十条 县级以上人民政府应当采取措施,防止水源枯竭和水体污染,保障城乡居民饮用水安全。饮用水水源所在地的乡(镇)人民政府以及村民集体组织有责任保护饮用水水源。


第三章城市供水工程建设和设施维护


第十一条 城市供水实行谁投资、谁受益,鼓励社会资金投资城市供水行业。

第十二条 新建、改建、扩建城市供水工程(包括取水工程、净水工程、输配水工程,下同),应当按照城市供水规划实施。城市供水管网建设,应当同时安排排污管网和城市消防用水设施建设。

第十三条 城市供水工程的设计、施工和监理,必须由具有相应资质的设计、施工和监理单位承担。

城市供水工程的设计、施工和监理应当符合国家和省有关技术标准和规范。

第十四条 城市供水工程竣工后,应当按照国家和省有关规定组织验收。组织验收的部门应当通知城市供水行政主管部门参加。

未经验收或者验收不合格的城市供水工程,不得投入使用。

第十五条 扩大城市规模,应当按照城市供水规划,设置集中转输加压、城市供水管道、消火栓等配套设施。新建、改建、扩建城市建筑,其高度超过国家规定的水压标准的,建设单位应当设置转输加压站、蓄水池等二次城市供水设施,并由产权单位负责维护管理。

城市供水配套设施的设计、施工、使用应当与主体工程同时进行。

第十六条 城市新建、改建、扩建工程项目需要增加用水的,其工程项目总概算应当包括城市供水工程建设投资。

第十七条 用户自行建设的供水进户计量水表以外的供水输配管道及其附属设施,必须经城市供水企业验收合格并交其统一管理后,方可投入使用。

第十八条 自建设施供水的管网系统,不得擅自与城市公共供水管网系统相连接。因特殊情况确需连接的,必须经城市公共供水企业验收合格,并在管道连接处采取必要的防护措施。

禁止生产或者使用有毒、有害物质的单位将其生产、使用的用水管网系统与城市公共供水管网系统直接连接。

第十九条 禁止任何单位和个人在城市公共供水管道上直接装泵抽水。对水质、水压有特殊要求并自行采取措施加压的用户,必须设置中间水池间接加压。

第二十条 城市供水公共设施,从取水口至进户总水表(含进户总水表)由城市供水企业维护和管理;从进户总水表至用户的供水设施由所有者或者管理者负责维护和管理。

城市供水行政主管部门应当对城市供水设施的管理和维护实施监督、检查。

第二十一条 城市供水管道及其附属设施的建设必须与其他各项基础设施和公共设施建设相衔接。在规定的城市供水输配管道及其附属设施的地面和地下的安全保护范围内,

禁止从事下列活动:
(一)修建建筑物、构筑物;
(二)开沟挖渠或者挖坑取土;
(三)打桩或者顶进作业;
(四)其他损坏城市供水设施或者危害城市供水设施安全的活动。
在供水输配管道及其附属设施的上下或者两侧埋设其他地下管线的,应当符合国家和省有关技术标准和规范,并遵守管线工程规划和施工管理的有关规定。

第二十二条 涉及城市供水设施的建设工程,建设单位或者施工单位应当在开工前向城市供水企业查明地下供水管网情况;影响城市供水设施安全的,建设单位或者施工单位应当与城市供水企业商定相应的保护措施,并组织实施。

第二十三条 任何单位和个人未经依法批准,不得改装、迁移或拆除公共供水设施。

工程建设确需改装、迁移或拆除公共供水设施的,建设单位应当在申请建设工程规划许可证前,报经县级以上城市供水行政主管部门审核批准,并采取相应的补救措施。

第二十四条 城市供水企业安装的计费水表,由城市供水企业负责统一管理和维护,任何单位和个人不得擅自拆卸、启封;不得围压、堆占、掩埋。

第二十五条 城市消防用水设施实行专用,除火警用水外,任何单位和个人不得动用。因特殊情况确需动用的,必须征得城市供水企业的同意,并报公安消防部门批准。

城市公共消火栓由城市供水企业负责安装和维修管理,公安消防部门负责监督检查。


第四章城市供水经营和运行管理


第二十六条 城市供水企业应当建立健全水质检测制度,定期检验水源、出厂水和管网水的水质,防止二次污染,确保供水水质符合国家规定的标准。公共供水企业必须确保供水水质符合国家规定的饮用水卫生标准。

城市供水、卫生行政主管部门应当按照各自职责,对公共供水全过程进行监督、检查。

第二十七条 城市供水企业应当在供水输配管网上设立供水水压测压点,确保供水水压符合国家和省规定的标准。

城市供水行政主管部门应当对供水水压进行监督、检查。

第二十八条 城市供水企业或者供水设施的所有者应当按照各自职责,对供水设施进行检修、清洗和消毒,确保供水设施正常、安全运行。

第二十九条 城市供水企业或者供水设施的所有者应当按照规定的供水水压标准,保持不间断供水,不得擅自停止供水。

因供水工程施工或者供水设施检修等原因,确需临时停止供水或者降低供水水压的,应在临时停止供水或者降低供水水压前24小时通知用户,并向城市供水行政主管部门报告。

因发生灾害或者紧急事故,无法提前通知的,应当在抢修的同时通知用户,尽快恢复正常供水,并报告城市供水行政主管部门。

连续超过24小时不能恢复正常供水的,城市供水企业应当采取必要的应急供水措施,保证居民生活用水的需要。

前款规定的通知用户方式应当采取直接书面通知或其他易于用户知晓的方式。

第三十条 城市公共供水设施抢修时,有关单位和个人应当给予支持和配合。对影响抢修作业的设施或其他物件,施工单位可以采取必要的处置措施,同时通知产权所有者,事后应当及时恢复原状、给予适当补偿。应当给予补偿
的,由城市供水企业与产权所有者依法协商解决。

第三十一条 供水企业应当实行一户一表计量制,计量到户。
城市供水企业按用户计量水表的计量和水价标准收取水费。
用户应当按照合同约定缴纳水费。逾期不缴纳的,供水企业可以催缴,并可按照合同约定对用户收取违约金。

第三十二条 城市供水按照用水性质和用途实行分类、分级计价,鼓励用户节约用水。

城市供水水价的确定和调整,按价格管理权限和程序进行,城市供水企业不得自行确定和调整水价。城市供水水价管理办法,由省价格行政主管部门会同省有关行政主管部门制定,并应当向社会公布。

第三十三条 城市供用水双方应当签订供用水合同,明确双方的权利与义务。

第三十四条 禁止城市用水用户有下列行为:
(一)盗用城市供水;
(二)擅自向其他单位或者个人转供公共供水;
(三)擅自改变用水性质和用途。

第三十五条 城市供水企业使用的供水设备、供水管材、供水器具和水化学处理剂应当符合国家标准;国家尚没有制定统一标准的,应当符合地方标准。

禁止生产、销售和使用不符合标准的供水设备、供水管材、用水器具和水化学处理剂。

城市供水、质量技监、卫生等行政主管部门应当对供水设备、供水管材、用水器具和水化学处理剂的开发和使用依法进行监督、检查。

第三十六条 城市人民政府应当因地制宜采取有效措施,推广和采用先进节水型工艺、节水型生活用水器具,降低城市供水管网漏失率,提高生活用水效率。


第五章法律责任


第三十七条 城市供水企业违反本办法规定,有下列行为之一的,由城市供水行政主管部门予以处罚:
(一)供水水质不符合国家规定标准的,责令其改正,可处以5000元以上3万元以下的罚款;
(二)供水水压不符合国家规定标准的,责令其改正,可处以5000元以上2万元以下的罚款;
(三)擅自停止供水或者未履行停水通知义务的,责令其改正,可处以1000元以上1万元以下的罚款;
(四)未按规定对供水设施进行检修、清洗、消毒或者在供水设施发生故障后,未在规定时间内组织抢修的,责令其改正,可处以2000元以上2万元以下的罚款。

有前款所列行为之一,情节严重的,经县级以上人民政府批准,可以责令其停业整顿;造成损失的,赔偿损失;对负有直接责任的国有企业主管人员和其他负有直接责任的国有企业人员,由其所在单位或者上级机关给予行政或纪律处分。

第三十八条 违反城市供水规划未经批准兴建供水工程的,由城市供水行政主管部门责令其停止违法行为,可处以5000元以上3万元以下的罚款;对负有直接责任的国有企业主管人员和其他负有直接责任的国有企业人员,由其所在单位或者上级机关给予行政或纪律处分。

第三十九条 违反本办法规定,有下列行为之一的,由城市供水行政主管部门责令其改正,可处以500元以上3万元以下的罚款;造成损失的,赔偿损失;对负有直接责任的国有企业主管人员和其他负有直接责任的国有企业人员,由其所在单位或者上级机关给予行政或纪律处分:
(一)损坏供水设施或者危害供水设施安全的;
(二)涉及供水设施的建设工程施工时,未按规定的技术标准和规范施工或者未按规定采取相应的保护或者补救措施的;
(三)擅自改装、迁移、拆除公共供水设施或者虽经批准但未采取相应补救措施的;
(四)擅自将自建设施供水管网系统与城市公共供水管网系统连接的;
(五)将生产或者使用有毒、有害物质的生产用水管网系统与公共供水管网系统直接连接的。
有前款第(三)、(四)、(五)项所列行为之一,情节严重的,经县级以上人民政府批准,可以在一定时间内对其停止供水。

第四十条 违反本办法规定,有下列行为之一的,由城市供水行政主管部门予以处罚:
(一)盗用公共供水的,责令其改正,补交公共供水水费,可处以1000元以上1万元以下的罚款;
(二)擅自转供公共供水的,责令其改正,可处以200元以上5000元以下的罚款;
(三)在城市公共供水管道上直接装泵抽水的,责令其改正,可处以200元以上5000元以下的罚款;
(四)未经批准擅自通过消防专用供水设施用水的,责令其改正,可处以500元以上1000元以下的罚款;
(五)阻挠或者干扰供水设施抢修工作的,责令其改正,可处以200元以上5000元以下的罚款。
未按合同约定缴纳水费的,责令其补缴所欠水费,并按合同约定支付违约金。
有第一款第(一)、(二)、(三)、(四)项所列行为之一的和第二款行为的,经县级以上人民政府批准,可以在一定时间内对其停止供水。

第四十一条城市供水管理人员玩忽职守、滥用职权、徇私舞弊的,由其所在单位或者上级机关给予行政处分。

第四十二条违反本办法规定,构成犯罪的,由司法机关依法追究刑事责任。


第六章附则


第四十三条相关名词解释:
(一)城市公共供水是指城市供水企业以公共供水管道及其附属设施向城乡单位和居民的生活、生产和其他各项建设提供用水。
(二)自建设施供水是指城市的用水单位以其自行建设的供水管道及其附属设施向本单位的生活、生产和其他各项建设提供用水。
(三)城市供水企业是指从事城市原水供水、公共供水(包括二次供水)和自建设施供水的企业。
第四十四条乡(镇)村供水、用水及其管理活动,可以参照本办法执行。
第四十五条本办法自公布之日起施行。1999年1月15日省人民政府发布的《浙江省城市供水管理办法》(省政府令第109号)同时废止。


Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.